Skip to main content
Premium Trial:

Request an Annual Quote

Roche Launches $2.2B Debt Tender Offer

NEW YORK (GenomeWeb) – Roche announced late yesterday that it has commenced a $2.2 debt tender offer.

The Swiss pharmaceuticals, diagnostics, and research products giant said that it launched an offer to purchase for cash the 5.25 percent Senior Notes due 2035 issued by its Genentech subsidiary and the 7 percent Senior Notes due 2039 issued by Roche Holdings.

The Genentech Senior Notes have a principal outstanding amount of $500 million, while the Roche Holdings Senior Notes have a principal outstanding amount of $2.5 billion. It listed the Genentech notes as having a higher acceptance priority level.

The offer is set to expire on Nov. 26, 2014, unless Roche terminates or extends the offer before that time.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.